Literature DB >> 12967828

Photodynamic therapy for choroidal neovascularization secondary to choroidal nevus.

Dinu Stanescu1, Sandrine Wattenberg, Salomon Y Cohen.   

Abstract

PURPOSE: To describe a patient treated with photodynamic therapy for subfoveal choroidal neovascularization secondary to choroidal nevus.
DESIGN: Interventional case report.
METHODS: A 61-year-old woman presented with subfoveal choroidal neovascularization secondary to choroidal nevus and best-corrected visual acuity of 20/50. The choroidal neovascularization was treated with two verteporfin photodynamic therapy sessions, separated by 3 months.
RESULTS: The choroidal neovascularization was occluded after two sessions. Best-corrected visual acuity improved to 20/25 and remained stable throughout an 18-month follow-up.
CONCLUSION: Photodynamic therapy seems to be an effective treatment for subfoveal choroidal neovascularization secondary to choroidal nevus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967828     DOI: 10.1016/s0002-9394(03)00321-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  4 in total

Review 1.  Lasers for the treatment of intraocular tumors.

Authors:  Samuel K Houston; Charles C Wykoff; Audina M Berrocal; Ditte J Hess; Timothy G Murray
Journal:  Lasers Med Sci       Date:  2013-05       Impact factor: 3.161

2.  Choroidal neovascularization secondary to choroidal nevus simulating an inflammatory lesion.

Authors:  Samuray Tuncer; Ilknur Tugal-Tutkun
Journal:  Indian J Ophthalmol       Date:  2013-06       Impact factor: 1.848

3.  Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab.

Authors:  Milena L Cavalcante; Victor M Villegas; Aaron S Gold; Ludimila L Cavalcante; Marcela Lonngi; Nisha V Shah; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2014-07-22

4.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.